Caribou Biosciences, Inc.

Caribou is headquartered in the United States and its business is primarily organized around U.S.-based research, clinical development, and corporate operations. The company’s current revenue is not tied to product sales geography; instead, it comes from licensing and collaboration agreements that may involve third parties in multiple regions. As a clinical-stage biotech, its geographic exposure is driven more by where trials are run, where partners are located, and where regulatory approvals would be sought than by commercial sales footprints. The company also notes exposure to global capital markets and geopolitical conditions, which can affect financing access and development timelines.

Caribou faces the classic risks of a clinical-stage biotechnology company: long development timelines, uncertain clinical efficacy, regulatory dependence, and the possibility that it never reaches profitable commercialization. Its current business model depends on external financing and collaboration revenue, so capital market volatility, higher interest rates, and geopolitical disruption can directly constrain operations. The company also disclosed a Nasdaq listing compliance issue related to its share price, which adds financing and market-access risk. More broadly, competition in cell therapy and genome editing is intense, and larger rivals may have greater resources, manufacturing capacity, and clinical development experience.